Top 5 Most-Read SAP Content in 2025

Across the oncology landscape in 2025, innovation outpaced expectation. The most-read articles of the year featuring The American Journal of Managed Care®’s (AJMC®’s) strategic alliance partners (SAPs) reflected how quickly cancer care is evolving—not just through new drugs, but through smarter delivery models, operational redesign, and partnerships that help practices adapt in real time. From home-based monitoring that keeps patients safer between visits to subcutaneous immunotherapy poised to reshape infusion suites to community practices joining larger networks for stability and scale, AJMC’s SAP coverage captured the forces reshaping oncology care. Rounding out the list was a surge of interest in radiopharmaceutical therapies, which many experts believe could soon reach more patients than ever before.

Here are the top 5 most-read SAP articles in 2025.

From home-based monitoring and subcutaneous immunotherapy to expanded community cancer networks, 2025 marked a pivotal year in rethinking how cancer care is delivered. | Image: AJMC+Partnership+Seal.png

5. With Remote Patient Monitoring, Picking Tools Is Easier Than Change Management

Remote patient monitoring (RPM) and therapeutic monitoring are gaining traction in oncology, especially as practices look to support patients receiving advanced therapies like chimeric antigen receptor (CAR) T-cell and bispecific agents outside traditional hospital settings, according to a discussion held at the Community Oncology Alliance (COA) Payer Exchange Summit. Early users, such as community practices in Texas and Arkansas, have implemented electronic patient-reported outcomes and RPM to track symptoms, intervene early, and avert emergency department visits.

Read the full article.

4. With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”

The recent approval of a subcutaneous (sub-Q) formulation of the checkpoint inhibitor nivolumab marks a significant shift in cancer therapy delivery. At the Association for Cancer Care Center’s (ACCC’s) 51st Annual Meeting & Cancer Center Business Summit, Raghava Reddy Induru, MD, who is based in Albemarle, North Carolina, for Atrium Health Levine Cancer Institute, discussed how sub-Q administration trims infusion time significantly—in some cases saving nearly an hour compared with traditional IV—and opens the door to potential home administration. Beyond convenience, the shift could ease operational burden for infusion centers, improve scheduling flexibility, and enhance patient experience.

Read the full article.

3. With Thyme Care Partnership, AON Achieves $6M in Savings in EOM’s First Performance Period

In evidence that value-based oncology care is more than theory, American Oncology Network (AON), in partnership with Thyme Care, reported nearly $6 million in savings for Medicare during the first performance period of the Enhancing Oncology Model (EOM). Key to their success were multi-pronged interventions, from pharmacy strategies to reduce drug waste to virtual care navigation, real-time data analytics, and palliative support.

Read the full article.

2. NYOH’s Doyle on Joining OneOncology: “What We Value the Most Is Culture”

In a highlight of community oncology consolidation, New York Oncology and Hematology (NYOH) joined OneOncology as its 27th practice in 2025, in a move driven not by financial pressure but by shared values. According to NYOH’s president, culture and commitment to patient-first care were the deciding factors. Through the partnership, NYOH gains access to a unified oncology-specific electronic medical record, streamlined patient scheduling and engagement tools, and expanded access to advanced therapies, including CAR T cell, bispecific, and emerging molecular treatments.

Read the full article.

1. Will the Coming Radiopharmaceutical Wave Reach More Patients With Cancer?

Topping the list of most-read SAP content this year was the discussion by leaders from AON around radiopharmaceuticals, a rapidly growing sector that delivers targeted radiation directly to cancer cells using radioligand therapy. With the 2025 FDA approval of a new indication for Lutetium Lu 177 vipivotide tetraxetan (Pluvicto; Novartis Pharmaceuticals Corporation) in metastatic prostate cancer, experts said the pool of eligible patients could triple.

Read the full article.